\BOOKMARK [1][-]{section.1}{Summary of Research}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Background on Pharmacovigilance, AERS and Social Media}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Experimental Data}{section.1}% 3
\BOOKMARK [3][-]{subsubsection.1.2.1}{Tokenization Study of Data}{subsection.1.2}% 4
\BOOKMARK [3][-]{subsubsection.1.2.2}{A Vocabulary for Experimentation}{subsection.1.2}% 5
\BOOKMARK [2][-]{subsection.1.3}{Language Identification for Messages}{section.1}% 6
\BOOKMARK [2][-]{subsection.1.4}{Experimentation and Results}{section.1}% 7
\BOOKMARK [3][-]{subsubsection.1.4.1}{Class Separability Confirmed via Kullback-Leibler Divergence}{subsection.1.4}% 8
\BOOKMARK [3][-]{subsubsection.1.4.2}{Named Entity Recognition in Messages}{subsection.1.4}% 9
\BOOKMARK [3][-]{subsubsection.1.4.3}{Handling Multiple Drug Names}{subsection.1.4}% 10
\BOOKMARK [3][-]{subsubsection.1.4.4}{Sentiment Feature}{subsection.1.4}% 11
\BOOKMARK [3][-]{subsubsection.1.4.5}{Feature Selection, Training and Test Data Size}{subsection.1.4}% 12
\BOOKMARK [3][-]{subsubsection.1.4.6}{Classifier and Lexicon Selection}{subsection.1.4}% 13
\BOOKMARK [1][-]{section.2}{Discussion of Contributions}{}% 14
\BOOKMARK [1][-]{section.3}{Research Critique}{}% 15
\BOOKMARK [1][-]{section.4}{Literature Review}{}% 16
\BOOKMARK [1][-]{section.5}{Application Areas}{}% 17
\BOOKMARK [1][-]{section.6}{Concluding Remarks}{}% 18
\BOOKMARK [1][-]{section.7}{Paper Criteria \(Grading\)}{}% 19
\BOOKMARK [2][-]{subsection.7.1}{Sentiment, Named Entities and Classification}{section.7}% 20
\BOOKMARK [2][-]{subsection.7.2}{Support Vector Machines}{section.7}% 21
\BOOKMARK [2][-]{subsection.7.3}{Naive Bayes Classification}{section.7}% 22
\BOOKMARK [2][-]{subsection.7.4}{Feature Selection}{section.7}% 23
\BOOKMARK [2][-]{subsection.7.5}{Evaluation Metrics Used}{section.7}% 24
